CBD Pet Products Market Size, Share and Analysis Report By Animal Type (Dogs, Cats, Others), By Product Type (Oils & Tinctures, Chews & Treats, Capsules & Softgels, Powders & Food Additives, Other), By Indication (Joint Pain, Anxiety/Stress, Epilepsy, General Health/Wellness, Others), By Distribution (Pet Specialty Stores, E-commerce, Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2035

Report Overview

In 2025, the Global CBD Pet Products Market was valued at US$396.4 million, and between 2026 and 2035, this market is estimated to register a CAGR of 29.5%, reaching about US$5130.9 million by 2035. In 2025, North America led the market, achieving over 45.1% share with a revenue of US$ 178.76 Million.

The CBD Pet Products Market is growing primarily as a result of increased pet humanization and demand for alternative wellness treatments for companion animals. A key driver is regulatory ambiguity combined with increasing consumer acceptance of cannabidiol-based supplements, particularly in the United States, where the Food and Drug Administration continues to report that no CBD-based products are approved for animal food or veterinary use, despite enforcement actions and warning communications indicating increased oversight pressure. This regulatory conflict is the “current moving power” of the market innovation is advancing while compliance risk rises.

• In August 2024, The U.S. NIH (PMC archive) data shows that hemp-derived CBD for pets is highly safe, with only 2.10 adverse events and 0.01 serious events per 1 million administrations. This low-risk profile strengthens market confidence, supports adoption, and provides federally documented validation for post-market monitoring and regulatory compliance.

Key Takeaways

• The global CBD Pet Products Market was valued at US$396.4 Million in 2025.
• The global CBD Pet Products Market is projected to grow at a CAGR of 29.5% and is estimated to reach US$5130.9 million by 2035.
• Dogs accounted for a leading 63.4% share of the market in 2025, driven by high ownership rates and the accelerating humanization of pets among millennial and Gen Z households.
• Oils & Tinctures accounted for a leading 34.5% share of the market in 2025, preferred for their capacity to enable precise, weight-calibrated dosing across a wide range of animal sizes and conditions.
• Joint Pain accounted for a leading 32.4% share of the market in 2025, sustained by the lifelong palliative care demands of aging pet populations and the absence of curative alternatives.
• Pet Specialty Stores accounted for a leading 43.8% share of the market in 2025, favored for the face-to-face consumer education and product guidance that physical retail environments are positioned to provide.
• North America accounted for a leading 45.1% share of the market in 2025, supported by progressive legal frameworks, established retail infrastructure, and high per-capita spending on pet wellness products.

Another reason is the shift toward preventive pet healthcare, with veterinarians becoming more interested in non-opioid pain management options. Strict regulatory restrictions, a lack of defined dosing procedures, and product quality heterogeneity throughout unregulated supply chains are all significant constraints. High compliance uncertainty prevents large-scale commercialization.

The market includes a wide range of administration technologies, such as therapeutic-grade oils, tinctures, and edible treats or chews. The most rapidly expanding demand variables include the critical need for non-pharmaceutical chronic pain management and natural stress alleviation options for domestic pets. To ensure purity, the future picture calls for rigorous supply chain verification using transparent third-party Certificates of Analysis (COAs). Furthermore, the industry is embracing AI integration to support automated data analysis, digital veterinary tools, and hyper-personalized dosing algorithms based on an individual animal’s specific weight and metabolic demands.

Animal Type Analysis

Dogs represents dominant Segment in the Market.

Dogs accounted for a leading 63.4% share of the CBD pet products market. This dominance is due to higher pet ownership rates, increased consumer spending on canine wellness, and a growing preference for preventive healthcare in dogs, especially for age-related conditions. Dogs’ dominance is technically supported by standardized dosage frameworks, broader veterinary acceptance, and the higher frequency of chronic conditions like joint pain and anxiety, which drive repeat product use. Economically, larger household budgets for dogs versus other pets allow premium product uptake, reinforcing segment leadership.

• According to the American Pet Products Association (APPA) 2025–2026 National Pet Owners Survey, approximately 68 million U.S. households own at least one dog. This large canine population creates a substantial customer base for CBD oils, treats, and supplements, as pet owners increasingly seek wellness products to support mobility, anxiety management, and overall health in dogs.

Cats are the fastest-growing segment, Valuation milestones indicate significant expansion due to urbanization, rising feline adoption rates, and increasing owner willingness to use wellness supplements. Growth is driven by the adaptation of product formulations specific to feline metabolism, innovations in palatable treats and tinctures, and education campaigns highlighting CBD benefits for anxiety, stress, and chronic conditions. Technological factors, such as microencapsulation for precise dosing, further accelerate segment growth.

Product Type Analysis

Oils & Tinctures Lead in Formulation Preference of Pet Product Market.

In 2025, Oils and Tinctures held a dominant market position, accounting for 34.5% of the market share. The segment leads the market because it is easy to administer, offers flexible dosing options, and is absorbed quickly by pets. Pet owners and veterinarians often prefer oils and tinctures as the dosage can be adjusted according to the pet’s size, age, and health condition. Their growing use in pet wellness and therapeutic applications, along with the availability of a wide range of formulations, has further supported segment growth. The higher average selling price of oils and tinctures compared to some other product types also contributes to their leading revenue share in the market.

• According to the American Pet Products Association (APPA) 2025–2026 National Pet Owners Survey, U.S. pet industry expenditures was USD 158 billion in 2025, reflecting growing spending on premium pet wellness products, including CBD oils and tinctures.

Oils & Tinctures is the fastest-growing segment in the CBD Pet Products Market by product type. In 2025, making it the leading product category. The segment continues to gain strong demand because it is easy to administer and allows pet owners to adjust the dosage based on the pet’s size and specific needs. Many pet owners prefer oils and tinctures due to their quick absorption and versatility, as they can be given directly or mixed with food.

Indication Analysis

Joint pain relief dominates therapeutic demand.

Joint pain accounted for 32.4% of product use, owing to the frequency of osteoarthritis and age-related mobility difficulties in companion animals. Anxiety/stress management remains a significant secondary use case, reflecting increased behavioral wellness awareness. Technical leadership is linked to CBD’s specific pharmacological effects in inflammatory regulation and pain signaling. Economic variables include a greater readiness to spend for chronic-condition management vs preventative wellness.

• According to the American Veterinary Medical Association (AVMA) and veterinary orthopedic studies, approximately 20% of adult dogs are affected by osteoarthritis, making it one of the most common chronic conditions in companion animals.

General health and wellness applications, including as immune support and cognitive maintenance, are predicted to experience significant increase by 2030-2035. The functional supplements for geriatric pets are gaining popularity. Preventive care trends and increased veterinary research supporting CBD benefits are among the catalysts. Limited clinical data and regulatory monitoring may hinder adoption in the absence of sufficient standardization.

Distribution Analysis

Pet specialty stores dominate retail channels.

Pet specialty stores accounted for 43.8% of the market in 2025. This dominance is due to their high visibility, knowledgeable personnel, and trusted brand presence. E-commerce lags slightly, owing to differences in digital penetration across demographics. Technical experience in staff assistance, product selection plans, and cross-selling with other wellness items helps to support leadership. Economic advantages include larger transaction sizes and higher repeat purchase rates when compared to general retail.

• Rising expenditure on pet healthcare, which reached nearly USD 41 billion in 2025, has increased demand for wellness-focused retail channels, supporting the growth of pet specialty stores.

E-commerce channels are projected to be the fastest-growing distribution segment between 2026 and 2035. Valuation milestones indicate that use has accelerated due to convenience, subscription structures, and widespread accessibility. Drivers include digital marketing, AI-powered recommendation engines, and increased consumer trust in online pet wellness shopping. Logistical efficiencies in shipping and fulfillment contribute to growth.

Key Market Segments

By Animal Type

• Dogs
• Cats
• Others

By Product Type

• Oils & Tinctures
• Chews & Treats
• Capsules & Softgels
• Powders & Food Additives
• Other

By Indication

• Joint Pain
• Anxiety/Stress
• Epilepsy
• General Health/Wellness
• Others

By Distribution

• Pet Specialty Stores
• E-commerce
• Others

Regional Analysis

North America Held the Largest Share of the Global CBD Pet Products Market.

North America dominated the CBD Pet Products Market, accounting for 45.1% of the global market and reaching a value of USD 178.76 million in 2025. The region’s leadership is supported by high pet ownership rates, strong consumer awareness of pet wellness products, and the widespread availability of CBD-based pet supplements through retail stores, veterinary clinics, and e-commerce platforms. The United States remains the largest contributor to regional revenue, driven by increasing spending on premium pet care products and growing acceptance of hemp-derived CBD formulations for pets. The presence of established CBD manufacturers, advanced distribution networks, and favorable regulatory developments has further strengthened market growth. In addition, rising demand for natural solutions to support pet anxiety, mobility, and overall wellness continues to support product adoption across the region.

Asia-Pacific is emerging as the fastest-growing region in the CBD Pet Products Market during 2025 and 2026. Growth is being driven by expanding pet ownership, rising disposable incomes, and increasing awareness of pet health and nutrition across countries such as China, Japan, Australia, and South Korea. The rapid expansion of online pet care platforms has improved access to specialized wellness products, including CBD-based offerings. Growing urbanization and the trend of treating pets as family members are encouraging higher spending on premium pet products. Furthermore, increasing investments in pet healthcare infrastructure and the gradual introduction of hemp-derived wellness products are creating new opportunities for market expansion across the region.

Key Regions and Countries Covered in this Report:

• North America
  • The US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia & CIS
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of MEA

Market Drivers

Canine Supplement Adoption

Pet humanization is converting canine wellness supplements from discretionary purchases into recurring household expenditure, creating an established channel for CBD oils, chews and condition-specific formulations. According to the American Pet Products Association’s 2025 tracking, approximately 53% of US dog owners use supplements, representing a 56% increase from 2018, while its ownership data indicate that US pet-owning households increased by approximately 12% to 94 million during 2024. Cornell University research found that more than 80% of dogs with osteoarthritis experienced reduced pain in an early clinical study using CBD, and National Institutes of Health-indexed research identified 2 milligrams per kilogram administered twice daily as a studied canine dosage. These adoption and evidence signals contribute an estimated +4.2% to the baseline CAGR and are shifting suppliers from one-time tincture sales toward monthly chew subscriptions, weight-based product tiers and condition-led bundles, improving reorder frequency and customer lifetime value while lowering acquisition cost per recurring order.

Market Restraints

Federal Animal-Product Restrictions

The absence of federal authorization creates a structural hard stop for mainstream veterinary and pet-food distribution in the United States. According to the US Food and Drug Administration, cannabis-derived CBD has not been approved for any use in animals, CBD-containing animal foods introduced into interstate commerce are considered adulterated, and disease-treatment claims can cause a product to be classified as an unapproved new animal drug. The Association of American Feed Control Officials states that hemp-derived CBD lacks an approved animal-food ingredient definition, while the National Animal Supplement Council reported that the FDA issued warning letters to 3 pet-product businesses on 7 April 2025 covering unapproved drug claims and edible CBD products. This legal barrier subtracts an estimated -6.5% from the baseline CAGR by excluding conventional pet-food formulations, veterinary prescribing and risk-averse retail chains, forcing suppliers into narrower supplement channels and raising legal review, insurance and customer-acquisition costs while delaying investment in large-scale manufacturing and national distribution.

Market Challenges

Potency and Label Variability

Inconsistent formulation and testing create operational friction because pet owners cannot reliably translate label dosage into actual cannabinoid exposure. Cornell University analysis of 29 veterinary CBD products found that only 10 of 27 products making cannabinoid-content claims were within 10% of the declared concentration, 2 contained no cannabinoids and 4 contained detectable heavy metals. A National Institutes of Health-indexed 2024 study similarly concluded that most tested commercial CBD products were inaccurately labelled, while National Animal Supplement Council standards require certified suppliers to undergo independent audits every 2 years, random laboratory testing and adverse-event monitoring. This quality dispersion creates an estimated -4.0% friction drag by increasing batch-release testing, product-liability exposure, refund rates and retailer due diligence; credible suppliers must therefore implement lot-specific certificates of analysis, validated extraction controls and stability testing, potentially raising quality-assurance cost per unit but protecting premium pricing and reducing the probability of recalls or brand-damaging adverse events.

Market Opportunities

Feline-Specific Delivery Systems

Cat-focused CBD remains future white space rather than a current driver because commercial portfolios and published clinical evidence remain disproportionately concentrated on dogs, despite rapid growth in feline ownership. According to the American Pet Products Association’s 2025 reporting, US cat ownership increased by 23% during 2024 and households owning at least 3 cats were 36% above 2018 levels, while peer-reviewed owner research found CBD administration among only 13% of surveyed cat owners compared with 29% of dog owners. The UK Veterinary Medicines Directorate reports that no licensed veterinary CBD products are available, and veterinary evidence reviews identify materially fewer feline than canine dosage studies. An analyst unit-economic model calibrated to these institutional indicators estimates that species-specific low-dose chews, transdermal formats and palatable oils could reduce customer trial abandonment by 10–15%, increase repeat-order rates by 8–12% and expand gross margins by 3–5 percentage points through premium pricing, supporting approximately +2.5% potential CAGR upside if suppliers fund feline safety studies and dedicated delivery technology.

Market Share & Key Players Analysis

The global market for CBD pet products is highly fragmented, and in advanced countries like North America, it is gradually moving toward a loosely consolidated oligopolistic model. Global retail pipelines are not monopolistically controlled by a single entity. Rather, the industry is fiercely competitive, with hundreds of regional vendors, specialty organic pet products, and big human-focused CBD businesses vying for adjacent veterinary demand.

The global market is highly fragmented, with minimal entry barriers. Because unified, global FDA-style medical mandates are currently absent, new competitors can enter the market with little regulatory friction, resulting in dense, fragmented long-tail behavior at the regional retail level. To overcome this strong fragmentation and acquire higher market shares, top-tier corporations are under increasing consolidation pressures, prompting them to actively explore strategic mergers, brand acquisitions, and downstream supply chain integration. Despite these transitions, a distinct tier-1 oligopolistic layer dominates the terrain. These market leaders preserve significant competitive advantages by operating their own certified hemp farms and extraction facilities, employing vertical integration to secure profit margins and distinguish themselves from lower-cost, unverified alternatives.

Key Players

• Garmon Corp.
• Canna-Pet LLC
• CBD Living
• Charlotte’s Web, Inc.
• FOMO Bones
• Honest Paws LLC
• Green Roads
• HempMy Pet
• HolistaPet
• Joy Organics
• Laboratoire Francodex
• Pet Releaf
• PETstock
• Wet Noses Natural Dog Treat Co.

Key Development

• In March 2026, Garmon Corp. expanded its portfolio of hemp-derived pet wellness solutions, focusing on CBD oils and supplements designed to support pet mobility, stress management, and overall well-being. The company increased its distribution footprint through partnerships with specialty pet retailers and online sales channels, helping improve product availability across key markets.
• In January 2026, cbdMD acquired Bluebird Botanicals, expanding its cannabinoid portfolio and integrating advanced hemp extraction capabilities, including pet-focused products under Paw CBD. The acquisition strengthened vertical integration, improved supply chain control, and reinforced intellectual property ownership, reflecting ongoing consolidation in the CBD pet market to enhance scalability and regulatory readiness.

Geopolitical Impact Analysis

Geopolitical Risk and Market Implications on CBD Pet Products.

The CBD Pet Products Market has been significantly impacted by the ongoing geopolitical crisis in Eastern Europe, mainly due to supply chain interruption and raw material instability. Delivery of CBD isolates and carrier oils has been delayed due to disrupted logistics in hemp farming and processing, which is mostly focused in areas impacted by trade restrictions, border closures, and export penalties.

Market economics have been further impacted by the conflict-related volatility in energy prices. The landed cost of CBD pet products has been directly impacted by higher processing and transportation costs in impacted areas due to rising fuel and electricity prices. These pressures are especially severe for goods that need cold-chain logistics, including tinctures and nanoemulsion oils, which are susceptible to changes in storage temperature.

Geopolitical risk has also caused changes in consumer behavior. A preference for less expensive, domestically made CBD pet formulas has been fueled by increased inflation and economic uncertainty in import-dependent regions. Meanwhile, demand for premium, high-traceability products has intensified among urban pet owners seeking security in product origin and manufacturing standards.

The market in 2026 will be affected by two factors: supply-side limitations due to disruptions in raw materials and transportation, and demand-side recalibration toward reliable, robust domestic channels. Businesses can reduce geopolitical risk while preserving market expansion by adapting through localized sourcing, adaptable distribution plans, and open compliance reporting.

Report Scope